Cabozantinib maintenance to help stop pediatric cancer from growing
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies cabozantinib given after standard treatment to try to keep high-risk pediatric solid tumors from coming back or getting worse. It is offered to children and young adults whose cancer has not fully disappeared but is not progressing at the start of this maintenance phase.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 months to under 40 years at enrollment
- Be in good enough health/activity for treatment (performance score of at least 50)
- Have specific high-risk tumor types/flags (trial “strata”) and a non-progressing status at enrollment
- Finish prior cancer treatment and allow the required “waiting time” before starting cabozantinib
- Have adequate blood, kidney, liver, pancreas, and heart/QT rhythm test results around enrollment
- Be able to swallow intact tablets and meet medication/wound/scan timing rules (including starting within set timelines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This study tests cabozantinib, a targeted therapy that blocks tumor growth, in people with advanced neuroendocrine tumors who have already tried other treatments. It may offer a new option if your doctor plans to use this drug.
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.